AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02860741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REJOICE
Description: Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
Study NCT02860741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
Study NCT00879333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Study NCT00879333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus placebo
Description: Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
Study NCT00879333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Study NCT00879333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care (BSC)
Description: Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Study NCT00779714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + cisplatin
Description: paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
Study NCT00779714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan + cytarabine
Description: treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
Study NCT01685281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metadoxine (MG01CI)
Description: MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
Study NCT01685281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be similar in appearance (color and size) to the investigational product
Study NCT02672033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo accelerated hypofractionated IMRT
Study NCT02672033 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo accelerated hypofractionated IMRT
Study NCT02672033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02672033 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo pleurectomy/decortication
Study NCT03919721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Behavioral Analysis
Description: Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
Study NCT03936023 — intervention group
Intervention type: DRUG
Intervention: Saxagliptin
Description: Saxagliptin dispensing claim is the exposure
Study NCT03936023 — intervention group
Intervention type: DRUG
Intervention: Sulfonylurea
Description: 2nd generation sulfonylurea dispensing claim is used as the reference
Study NCT00873782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrograde high pressure transvenous perfusion with normal saline
Description: Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
Study NCT03500549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study NCT03500549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Description: Complement (C3) Inhibitor
Study NCT03500549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soliris
Description: Complement (C5) Inhibitor
Study NCT03500549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soliris
Description: Complement (C5) Inhibitor
Study NCT04063865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
Study NCT04063865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
Study NCT04031924 — intervention group
Intervention type: OTHER
Intervention: Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity
Description: All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
Study NCT04331028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: A shockwave therapy device will be applied in the alveolar socket area of a maxillary tooth, 2 weeks after tooth extraction was performed.
Study NCT01892241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys(Roche)
Description: 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
Study NCT01892241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: continual entecavir therapy(0.5 mg orally once daily)
Study NCT02702167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: 10 Hz active stimulation, once daily
Study NCT02702167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS
Description: 1 Hz active stimulation, once daily
Study NCT00381485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
Study NCT02702167 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation, once daily
Study NCT02579863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02579863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: oral capsules
Study NCT02579863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: oral capsules
Study NCT02579863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral tablets
Study NCT02579863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral tablets
Study NCT01060124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl D-trans
Description: Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
Study NCT00367705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3®
Description: 1-2 sachets/day per os, 6 months
Study NCT00367705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 sachets/day per os, 6 months
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Study NCT01685450 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echodia® hand-held equipment
Study NCT01442428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
Study NCT01442428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
Study NCT01442428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
Study NCT01442428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Study NCT00381485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Study NCT01442428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
Study NCT01442428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Atorvastatin placebo
Study NCT04430478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volume flow guided angioplasty
Description: Volume flow measurements using DUS will be obtained at the end of each balloon dilation, at 24 hours, 6 months, and one year after index procedure.
Study NCT02332954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vortioxetine
Description: The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
Study NCT00405444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
Study NCT03788200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bracing
Description: Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
Study NCT03788200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior C1-C2 instrumented fusion
Description: Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
Study NCT00405444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
Study NCT00381485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate MDI (MF MDI)
Description: MF 400 mcg via metered dose inhaler twice daily for 12 weeks
Study NCT03478527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx® powder
Description: Participants will take in a daily dose of 4.4g for 28 consecutive days
Study NCT03478527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Participants will take in a daily dose of 4.4g for 28 consecutive days
Study NCT01345487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetable Protein
Description: Vegetable protein in the form of fava beans/split peas
Study NCT01345487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vegetable Protein
Description: Vegetable protein in the form of fava beans/split peas
Study NCT01345487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal protein
Description: Protein in the form of minced pork/beef
Study NCT02483208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY81-8973
Description: BAY81-8973 infusion to analyze pharmacokinetics
Study NCT04073953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPQ
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study NCT02483208 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Advate
Description: Advate infusion to analyze pharmacokinetics.
Study NCT01918774 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive behavior therapy for work success (CBTw)
Description: The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
Study NCT04189159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPT
Description: PROMPT treatment is consistent with the principles of motor learning, in that every session includes a blocked pre-practice followed by variable and distributed practice and a gradual, hierarchical increase of complexity. Speech motor goals are integrated in goals for language and functional communication. During a PROMPT session tactile-kinesthetic-proprioceptive inputs are consistently provided, in order to shape speech movements, to give information on sequencing and timing and to introduce constraints for the reduction of degrees of freedom at the articulators' level in favour of motor control.
Study NCT01768013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90105
Description: Once daily for four weeks
Study NCT01740726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: 18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
Study NCT01740726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
Study NCT04073953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPQ
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study NCT00268476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Study NCT04073953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
Study NCT05011045 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05011045 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive Assessment
Description: Undergo neurocognitive function assessment
Study NCT05011045 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study NCT05011045 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT02804022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPIA analgesia
Description: Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
Study NCT02804022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
Study NCT05927948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laight therapy, NICE V3.1 device
Description: Laight therapy is a non-invasive method of treatment for HS and acne developed in Germany which utilizes a combination of radiofrequency and intense pulsed light exposure. Three passes of the device, all coupled with radiofrequency, are used in the proposed treatment area. The first pass encompasses wavelengths between 420 nm and 1200 nm, the second between 510 nm and 1200 nm, and the third pass between 690 nm and 1200 nm.
Study NCT03713619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: Secukinumab 300mg every 2 or every 4 weeks
Study NCT03713619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg every 2 or every 4 weeks
Study NCT02874885 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT03444376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-188E
Description: GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device
Study NCT03444376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: pembrolizumab(100mg/4mL/vial), Intravenous administration
Study NCT05729685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training
Description: The interval training group trained using the interval method. During the exercise sessions the participants ran each bout at an intensity corresponding to 90% of PTV. PTV was used to prescribe the exercise intensity at the INT group. The duration of the running-bouts was equal to ¼ of the individual time to exhaustion at 90% of PTV (determined during the CV testing) followed by passive rest equal to 2/3 of exercise duration. The duration of the exercise-bouts was individualized based on the time to exhaustion at 90% of PTV to reduce the between subject's variability. The participants terminated each exercise session when an RPE value of 17 was reached. Running bout duration and intensity were adjusted after 7 training sessions (during the 3rd week) following a reassessment of the time to exhaustion at 90% of the new PTV achieved during mid-testing as a result of training.
Study NCT05729685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous training
Description: The continuous group trained using the continuous method. During the training sessions the participants ran with an intensity corresponding to -2,5% of CV until they reported a rating of 17 at the 6-20 Borg's scale. Running velocity was adjusted after 7 training sessions (during the 3rd week) after reassessment of CV. CV was used to determine the exercise intensity in the CONT group to ensure that all individuals would ran at the heavy intensity domain and be able to complete at least 15 min of continuous running, and to minimize the high inter-individual variations in endurance time at intensities near the upper limit of the heavy intensity domain. Using PTV to determine the intensity in the CONT group, would increase the possibility for trainees to exercise at different exercise intensity domains.
Study NCT02754856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02754856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02754856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo liver surgery
Study NCT02754856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT02334592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sunbed tanning
Description: Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act